Compare · BLU vs NVO
BLU vs NVO
Side-by-side comparison of BELLUS Health Inc. (BLU) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLU and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 306.0x BLU ($612.8M).
- NVO has hit the wire 11 times in the past 4 weeks while BLU has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 7 for BLU).
- Company
- BELLUS Health Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $612.8M
- $187.53B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 0
- 11
- Recent ratings
- 7
- 25
BELLUS Health Inc.
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BLU
- SEC Form SC 13G filed by BELLUS Health Inc.
- SEC Form SC 13G/A filed by BELLUS Health Inc. (Amendment)
- SEC Form 15-12G filed by BELLUS Health Inc.
- From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
- SEC Form S-8 POS filed by BELLUS Health Inc.
- SEC Form S-8 POS filed by BELLUS Health Inc.
- SEC Form 6-K filed by BELLUS Health Inc.
- SEC Form 6-K filed by BELLUS Health Inc.
- Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health
- SEC Form 6-K filed by BELLUS Health Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates